|Collinearity of protease mutations in HIV-1 samples with high-level protease inhibitor class resistance.|
|Jump to Full Text|
|PMID: 23085775 Owner: NLM Status: MEDLINE|
|OBJECTIVES: To determine whether pan-protease inhibitor (PI)-resistant virus populations are composed predominantly of viruses with resistance to all PIs or of diverse virus populations with resistance to different subsets of PIs.
METHODS: We performed deep sequencing of plasma virus samples from nine patients with high-level genotypic and/or phenotypic resistance to all licensed PIs. The nine virus samples had a median of 12 PI resistance mutations by direct PCR Sanger sequencing.
RESULTS: For each of the nine virus samples, deep sequencing showed that each of the individual viruses within a sample contained nearly all of the mutations detected by Sanger sequencing. Indeed, a median of 94.9% of deep sequence reads had each of the PI resistance mutations present as a single chromatographic peak in the Sanger sequence. A median of 5.0% of reads had all but one of the Sanger mutations that were not part of an electrophoretic mixture.
CONCLUSIONS: The collinearity of PI resistance mutations in the nine virus samples demonstrated that pan-PI-resistant viruses are able to replicate in vivo despite their highly mutated protease enzymes. We hypothesize that the marked collinearity of PI resistance mutations in pan-PI-resistant virus populations results from the unique requirements for multi-PI resistance and the extensive cross-resistance conferred by many of the accessory PI resistance mutations.
|Farbod Babrzadeh; Vici Varghese; Mary Pacold; Tommy F Liu; Pål Nyrén; Celia Schiffer; W Jeffrey Fessel; Robert W Shafer|
Related Documents :
|23840745 - Detection of infectious laryngotracheitis virus by real-time pcr in naturally and exper...
23222205 - Hepatitis a virus infection and the waste handling industry: a seroprevalence study.
24655395 - Active surveillance for avian influenza virus, egypt, 2010-2012.
23184775 - Biomineralization-based virus shell-engineering: towards neutralization escape and trop...
21471095 - Viral infection in acute exacerbation of idiopathic pulmonary fibrosis.
8031235 - Analysis of sites of foot and mouth disease virus persistence in carrier cattle via the...
|Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2012-10-19|
|Title: The Journal of antimicrobial chemotherapy Volume: 68 ISSN: 1460-2091 ISO Abbreviation: J. Antimicrob. Chemother. Publication Date: 2013 Feb|
|Created Date: 2013-01-14 Completed Date: 2013-06-10 Revised Date: 2013-07-11|
Medline Journal Info:
|Nlm Unique ID: 7513617 Medline TA: J Antimicrob Chemother Country: England|
|Languages: eng Pagination: 414-8 Citation Subset: IM|
|Stanford Genome Technology Center, Stanford University, Stanford, CA 94305, USA.|
|APA/MLA Format Download EndNote Download BibTex|
Drug Resistance, Viral*
HIV Protease / genetics*
HIV Protease Inhibitors / pharmacology*
HIV-1 / drug effects*, genetics*, isolation & purification
High-Throughput Nucleotide Sequencing
Microbial Sensitivity Tests
Plasma / virology
RNA, Viral / genetics
|AI068581/AI/NIAID NIH HHS|
|0/HIV Protease Inhibitors; 0/RNA, Viral; EC 3.4.23.-/HIV Protease|
Journal ID (nlm-ta): J Antimicrob Chemother
Journal ID (iso-abbrev): J. Antimicrob. Chemother
Journal ID (publisher-id): jac
Journal ID (hwp): jac
Publisher: Oxford University Press
© The Author 2012. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
Received Day: 5 Month: 5 Year: 2012
Revision Requested Day: 5 Month: 7 Year: 2012
Revision Received Day: 31 Month: 7 Year: 2012
Accepted Day: 12 Month: 9 Year: 2012
Print publication date: Month: 2 Year: 2013
Electronic publication date: Day: 19 Month: 10 Year: 2012
pmc-release publication date: Day: 19 Month: 10 Year: 2012
Volume: 68 Issue: 2
First Page: 414 Last Page: 418
PubMed Id: 23085775
Publisher Id: dks409
|Collinearity of protease mutations in HIV-1 samples with high-level protease inhibitor class resistance|
|Tommy F. Liu2|
|W. Jeffrey Fessel5|
|Robert W. Shafer2|
1Stanford Genome Technology Center, Stanford University, Stanford, CA, USA
2Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA
3Department of Biotechnology, AlbaNova University Center, KTH, Stockholm, Sweden
4Department of Biochemistry, University of Massachusetts Medical Center, Worcester, MA, USA
5Kaiser-Permanente Medical Care Program Northern California, Clinical Trials Unit, San Francisco, CA, USA
|*Corresponding author. 300 Pasteur Drive, Grant building Room S-146, Stanford University Medical Center, Stanford, CA, USA-94305. Tel: +1-650-723-8291; Fax: +1-650-725-2395; E-mail: email@example.com
†These authors contributed equally to the manuscript.
HIV-1 isolates with high-level resistance to most or all protease inhibitors (PIs) are not uncommon in patients who have received multiple PI-containing regimens.1,2 Considering the decreased fitness associated with PI resistance mutations and their disparate and often antagonistic effects on different PIs,3–5 we sought to determine whether pan-PI-resistant virus populations comprise viruses with resistance to all PIs or virus subpopulations with different patterns of PI resistance mutations. Because standard genotypic resistance testing using dideoxynucleotide terminator (Sanger) sequencing rarely detects variants present in proportions below 20%–30% of circulating viruses,6 we performed deep sequencing of pan-PI-resistant virus samples using the 454 Life Sciences/Roche Molecular Systems pyrosequencing technology.
Patients included HIV-1-infected individuals in the Kaiser Permanente Medical Care Programme—Northern California undergoing Sanger genotypic resistance testing at Stanford University and phenotypic resistance testing at Monogram Biosciences. Cryopreserved plasma virus samples with HIV-1 RNA levels ≥4.5 log copies/mL and high-level phenotypic or genotypic resistance to all PIs were selected for deep sequencing. The Stanford University Human Subjects Panel approved the study.
Extracted plasma viral RNA was reverse transcribed with random primers and Superscript III RT. cDNA titres were estimated by limiting dilution PCR to include >120 amplifiable virus templates in a nested PCR protocol using Expand High Fidelity PLUS DNA polymerase to generate an amplicon encompassing HIV-1 protease. Second-round primers were tailed with a sample-specific barcode. Bidirectional deep sequencing was performed on a GS-FLX sequencer. Each sample pool was loaded in a 70 × 75 mm PicoTiter plate fitted with an eight-lane gasket.
Flowgram format files were processed to generate paired files containing FASTA sequence reads and Phred-equivalent quality scores. To reduce artefact, trimmed sequence reads with <150 nucleotides, nucleotide quality scores <10 or mean quality scores <25 were excluded.7 Sequence reads were de-multiplexed using the 5′ primer and barcode, and aligned to the Sanger sequence using MosaikAligner.8
To distinguish authentic variants from PCR and pyrosequencing artefacts, we estimated the technical error rate by deeply sequencing plasmid HIV-1 pNL43 protease. The plasmid mismatch error rate was 0.20% with a nucleotide position-specific median mismatch error rate of 0.14% (range 0%–1.2% per nucleotide position). Minority variants were defined as mutations not detected by Sanger sequencing occurring in ≥1.0% of sequence reads in a proportion >5.0 times the variant's proportion in the control sequence.
Minority variant mutations were classified into five categories: (i) PI resistance mutations; (ii) protease variants present in >0.1% of sequences from individuals in the Stanford HIV Drug Resistance Database (HIVDB);9 (iii) residual wild-type variants defined as consensus B amino acids in samples for which the Sanger sequence contained a mutation; (iv) unusual variants defined as mutations present in <0.01% of non-hypermutated sequences in HIVDB; and (v) silent mutations defined as synonymous nucleotide differences from the Sanger sequence.
Non-polymorphic PI-selected mutations10 and L10I/V, V11I, L33F and A71V/T were classified as PI resistance mutations. The subset D30N, V32I, M46I/L, I47V/A, G48V/M, I50L/V, I54V/L/M/T/A/S, L76V, V82A/T/F/S/L, I84V, N88D/S and L90M were classified as major mutations.11
To characterize intra-patient nucleotide and amino acid sequence heterogeneity, we clustered reads with identical or nearly identical sequences defined as sequences differing only in length (provided they encompassed ≥180 nucleotides); a stop codon; a nucleotide deletion; or a mutation present in only one strand in a proportion <0.25%.
Nine plasma samples met the inclusion criteria (Table 1). The darunavir phenotype was not available for one sample; three samples had intermediate phenotypic tipranavir resistance. The patients had received a median of five PIs for a median of 8.5 years. The median time of uninterrupted therapy prior to sample collection was 12 months (range 5–32 months). The median number of PI resistance mutations per sample was 12 (range 10–14).
We generated a median of 2134 high-quality sequence reads per sample (range 830–923), including a median of 1331 forward reads encompassing positions 10–84 (range 527–933), and 966 reverse reads encompassing positions 30–99 (range 263–1990). No reads encompassed all PI resistance positions (10–90).
The second column in Table 2 shows the proportion of deep sequence reads with each PI resistance mutation present in the Sanger sequence: 88 (80%) of the 110 PI resistance mutations occurred in ≥99.0% of sequence reads. Of the remaining 22 PI resistance mutations, the eight underlined mutations were present as electrophoretic mixtures by Sanger sequencing and occurred in a median of 54.5% of reads (range 11.4%–79.1%). The remaining 14 mutations were present in a median of 96.1% of reads (range 79.1%–98.5%).
Table S1 (available as Supplementary data at JAC Online) shows that of the PI resistance mutations present in an unmixed form by Sanger sequencing (range 9–12), a median of 94.9% of reads per sample (range 80.6%–97.6%) contained each mutation within its coverage (10–84 for forward reads and 30–90 for reverse reads). A median of 5.0% of reads contained all but one PI resistance mutation (range 2.4%–18.9%) and a median of 0.1% contained all but two mutations (range 0%–1.6%). Figure S1 (available as Supplementary data at JAC Online) shows the amino acid alignments of all distinct viral variants in ≥1.0% of forward or reverse deep sequence reads.
Columns 3–7 in Table 2 show the five categories of minority variant mutations. The nine samples contained 54 amino acid and 78 silent minority variants. A median of six amino acid minority variants was detected per sample (range 2–11). Of the 38 minority variant amino acid mutations between codons 30 and 84, all but three were present in both forward and reverse reads.
Eighteen of 54 minority variant amino acid mutations were PI resistance mutations, including two major mutations: N88S (1.7% of 1456 reads) and I50V (20.2% of 38129 reads). Three minority variant major PI resistance mutations were present in 0.5%–1.0% of reads, including V82T (0.8%) and I47A (0.6%) in sample 6585 and V82A (0.8%) in sample 4736 (data not shown).
Twenty-four (43%) minority variants were known protease variants and seven (13%) were residual wild-type amino acids. The six unusual variants comprised 11% of amino acid minority variants and 4.5% of all minority variants.
Although the pan-PI-resistant viruses shared many PI resistance mutations, including L10I/V/F, V32I, L33F, M46I, I47V, I54M/L/V, A71V/I, G73S/T/C, I84V, L89V and L90M, their sequences were divergent. The mean nucleotide distance between the nine Sanger sequences was 12.4% ± 2.1% and between deep sequence reads from different samples was 11.6% ± 0.6% (Figure S2 available as Supplementary data at JAC Online). By contrast, the mean intra-sample diversity was 1.2% (range 0.7%–2.0%).
Deep sequencing of plasma virus samples from nine patients with high-level phenotypic and/or genotypic resistance to all approved PIs showed that these pan-PI-resistant virus populations were composed of viruses with genotypic resistance to all PIs rather than of subpopulations with resistance to different PIs. Because Sanger sequencing is able to detect variants present in proportions as low as 20%–30%, the absence of electrophoretic mixtures at nearly all PI resistance positions made it likely a priori that the proportions of each mutation would be ≥70%–80% of the plasma virus population. However, the finding that >99% of sequence reads contained all or all but one of the median 11 unmixed PI resistance mutations could only be determined by deep sequencing.
Because the GS-FLX reagents used yielded read lengths of 200–250, the forward primer reliably encompassed positions 10–84 and the reverse primer reliably encompassed positions 30–99, but neither encompassed all PI resistance positions. However, considering the overlap between positions 30 and 84, the concordance between forward and reverse reads and the near-complete absence of minority variants at unmixed PI resistance positions, it is overwhelmingly likely that our findings would not have differed had positions 10–90 been covered by both sets of primers.
One limitation of deep sequencing is that PCR-induced template-product bias complicates the quantification of sequenced minority variants. Indeed, a novel method, which attaches a barcode to each cDNA molecule prior to PCR, overcomes this limitation and also helps to distinguish true minority variants from technical artefacts.12 Although we did not use this method, our limiting dilution analysis showed that >120 cDNA templates were present in each sample prior to PCR. In addition, our post hoc analyses showed that >95% of minority variants occurring in ≥1.0% of reads were silent mutations or previously reported variants. This finding suggests that ∼100 genomes per sample were likely to have been successfully amplified and sequenced.
Although at least eight of the nine viruses had PI resistance mutations at positions 10, 32, 33, 46, 54, 71, 73, 84 and 90, the pan-PI-resistant viruses were genetically distinct, indicating that the emergence of this pattern of protease mutations is an extraordinary example of convergent virus evolution. The collinearity of PI resistance mutations in these samples, moreover, indicates that pan-PI-resistant viruses are able to replicate in vivo despite their highly mutated protease enzymes.
The study was funded in part by NIAID AI068581 and California HIV Research ProgramID08-ST-031
None to declare.
Table S1 and Figures S1 and S2 are available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/).Supplementary Data
Click here for additional data file (supp_dks409_dks409supp.doc)
|1.||Talbot A,Grant P,Taylor J,et al. Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitorsAntimicrob Agents ChemotherYear: 20105424739 doi:10.1128/AAC.00096-10. 20368406|
|2.||Doherty KM,Nakka P,King BM,et al. A multifaceted analysis of HIV-1 protease multidrug resistance phenotypesBMC BioinformaticsYear: 201112477 doi:10.1186/1471-2105-12-477. 22172090|
|3.||Weinheimer S,Discotto L,Friborg J,et al. Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbonesAntimicrob Agents ChemotherYear: 200549381624 doi:10.1128/AAC.49.9.3816-3824.2005. 16127058|
|4.||Wiesmann F,Vachta J,Ehret R,et al. The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors atazanavir and saquinavir: is there a clinical advantage?AIDS Res TherYear: 201187 doi:10.1186/1742-6405-8-7. 21314993|
|5.||Ziermann R,Limoli K,Das K,et al. A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavirJ VirolYear: 20007444149 doi:10.1128/JVI.74.9.4414-4419.2000. 10756056|
|6.||Gianella S,Richman DD. Minority variants of drug-resistant HIVJ Infect DisYear: 201020265766 doi:10.1086/655397. 20649427|
|7.||Huse SM,Huber JA,Morrison HG,et al. Accuracy and quality of massively parallel DNA pyrosequencingGenome BiolYear: 20078R143 doi:10.1186/gb-2007-8-7-r143. 17659080|
|8.||Li H,Homer N. A survey of sequence alignment algorithms for next-generation sequencingBrief BioinformYear: 20101147383 doi:10.1093/bib/bbq015. 20460430|
|9.||Rhee SY,Gonzales MJ,Kantor R,et al. Human immunodeficiency virus reverse transcriptase and protease sequence databaseNucleic Acids ResYear: 200331298303 doi:10.1093/nar/gkg100. 12520007|
|10.||Shahriar R,Rhee SY,Liu TF,et al. Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutationsAntimicrob Agents ChemotherYear: 200953486978 doi:10.1128/AAC.00592-09. 19721070|
|11.||Rhee SY,Taylor J,Fessel WJ,et al. HIV-1 protease mutations and protease inhibitor cross-resistanceAntimicrob Agents ChemotherYear: 201054425361 doi:10.1128/AAC.00574-10. 20660676|
|12.||Jabara CB,Jones CD,Roach J,et al. Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer IDProc Natl Acad Sci USAYear: 20111082016671 doi:10.1073/pnas.1110064108. 22135472|
Protease inhibitor (PI) history, protease mutations and PI susceptibilities of nine pan-PI-resistant HIV-1 isolates
|Sample||VL||CD4||PIs (years)||PIs (number)||PIsa||Mutations detected by direct PCR Sanger sequencingb||RC (%)||ATV c||FPV||IDV||LPV||NFV||SQV||TPV||DRV|
|1456||4.5||173||9||6||SQV, NFV, IDV/r, APV/r, TPV/r, LPV/r||10I/V, 32I, 33F, 35D, 36M/I, 37S, 46I, 47V, 53F/L, 54L, 55R, 63P, 64V, 66V, 71V, 73T, 79P/A, 84V, 90M, 93I/L||9||98||120||24||140||65||58||3.3||NA|
|1459||4.5||255||8||5||IDV, NFV, SQV/r, APV/r, LPV/r||10I, 13V, 19I, 32I, 33F, 46I, 47V, 54M, 64V, 71V, 73C, 77I, 84V, 90M, 95L||2||38||15||25||85||50||9.4||6.3||142|
|1556||5.7||12||9||7||IDV, NFV, SQV/r, APV/r, LPV/r, TPV/r, DRV/r||10F, 11I, 12P, 13V, 15V, 19P, 20T, 32I, 33F, 35G, 36I, 54I/V, 62V, 63P, 70T, 71I, 73S, 79A, 84V, 89V, 90M||52||172||108||27||62||83||41||9.8||134|
|4736||4.7||208||12||≥3||IDV, LPV/r, TPV/r||10V, 11I, 13V, 14R, 15V, 20T, 32I, 33F, 36I, 41K, 46L, 54L, 57K, 60E, 63P, 68E, 70T, 71I, 72I/M, 73S, 84V, 89V, 90M, 93L||13||109||>200||21||87||94||93||7||239|
|6585||4.7||41||3.5||5||IDV, SQV/r, NFV APV/r, LPV/r||10V, 12V/D, 13V, 15V, 20M, 32I, 33F, 43T, 46I, 47V, 54M, 60E, 61D, 62V, 63P, 67Y, 69K, 71I, 72L, 73S, 77I, 82A, 89V, 90M||96||88||>200||88||>200||76||12||12||112|
|7118||5.1||105||7.5||5||SQV/r, LPV/r, LPV/r + APV, ATV/r, DRV/r||10F, 11V/I, 13V, 16A, 19L/V, 33F, 34Q, 43I, 46L, 51A, 54M, 63P, 64M, 71V, 72M, 73A, 84V, 90M||NA||111||>200||47||>200||51||>200||9.5||140|
|7859||4.5||162||11||5||NFV, IDV, APV, LPV/r, ATV/r||10I, 13V, 15V/I, 19I/L, 20A, 32I, 33F, 36I, 46I, 47V, 54M, 63P, 71V, 74P, 77I, 84V, 89V, 90M, 93L||3||50||>200||40||>200||52||37||17||286|
|14311||4.8||136||7||3||APV/r, ATV/r, LPV/r, FPV + LPV/r||10F, 11I, 32I, 35A, 36I, 46I, 47V, 54M, 57K, 62V, 63P, 64V, 73T, 74A, 84V,89V,90M||4||120||>200||48||>200||50||22||8||245|
|38129||4.5||22||≥4||≥3||IDV, ATV/r, DRV/r||10I, 11I, 12K, 13V, 20V, 32I, 33F/L, 35G, 36I, 37D/N, 46I, 47V, 54M, 57K, 58E, 63P, 64V, 71V/I, 73S, 84V/I, 89V, 90M||3||97||>200||55||>200||80||26||>200||>200|
VL, plasma HIV-1 RNA level (log copies/mL); CD4, CD4+ lymphocytes (cells/mm3); RC, replication capacity; ATV, atazanavir; DRV, darunavir; FPV, fosamprenavir; IDV, indinavir; LPV, lopinavir; NA, not available; NFV, nelfinavir; SQV, saquinavir; TPV, tipranavir.
The GenBank accession numbers for the direct PCR sequences are as follows: GQ211137 (1456), AY796708 (1459), pending (1556), GQ212652 (4736), AY797430 (6585), pending (7118), GQ213748 (7859), pending (14311), GQ213273 (38129).
a‘/r’ following the PI abbreviation indicates ritonavir co-administration for pharmacokinetic boosting; ‘+’ indicates the simultaneous use of two PIs.
bMutations in bold are major PI resistance mutations. Underlined mutations are non-polymorphic PI-selected mutations and the minimally polymorphic PI-selected mutations L10IV, V11I, L33F and A71VT.
cThe last eight columns indicate the fold decrease in susceptibility for each PI as determined by the PhenoSense assay. Those in bold are considered highly resistant according to the PhenoSense clinical cut-off. Each of the nine viruses displayed high-level ritonavir resistance (data not shown).
Percentage of deep sequence reads with mutations detected by direct PCR sequencing and with minority variant mutations
|Sample||PI resistance mutations detected by direct PCR sequencinga (percentage of deep sequencing reads with each mutation)||Mutations not detected by direct PCR sequencing (minority variant mutations)
|PI resistance mutationsa (%)||other variants (%)||residual WTb (%)||unusual variantsc (%)||silent variantsd (no.)|
|1456||L10I (52.6), L10V (46.5), V32I (99.4), L33F (99.7), M46I (99.9), I47V (99.9), F53L (21.4), I54L (99.0), A71V (86.0), G73T (99.9), P79A (11.6), I84V (99.4), L90M (97.3)||K43T (15.4), A71I (14.0), N88S (1.7)||G16A (7.5), I15V (5.0), Q18E (1.4), K20R (1.3)||9|
|1459||L10I (100), V32I (100), L33F (99.9), M46I (99.9), I47V (99.9), I54M (99.2), A71V (99.7), G73C (100), I84V (99.9), L90M (100)||I13V (12.4), R41K (2.7), R87K (1.6), C67W (1.2), Q18H (1.2)||V77 (1.0)||D29G (2.8)||6|
|1556||L10F (79.9), V11I (99.7), K20T (99.4), V32I (99.4), L33F (99.8), E35G (98.5) I54V (74.0), A71I (95.3), G73S (99.6), I84V (99.8), L89V (99.8), L90M (99.4)||L10V (18.1), A71V (4.5), T74P (1.8), L10I (1.3)||K70E (7.5), K43R (3.0), R57K (2.2), T12S (1.4), R41K (1.2)||E35 (1.5), L10 (1.1)||12|
|4736||L10V (99.6), V11I (99.9), K20T (99.0), V32I (99.9), L33F (98.6), M46L (99.3), I54L (99.3), A71I (100), G73S (99.8), I84V (99.4), L89V (99.1), L90M (99.7)||L33 (1.3)||G49E (4.1)||3|
|6585||L10V (100), V32I (100), L33F (94.2), K43T (95.6), M46I (99.7), I47V (99.4), I54M (99.3), A71I (99.0), G73S (100), V82A (99.1), L89V (100), L90M (100)||Q58E (3.3), K55R (1.5), V11I (1.1)||Q61N (14.1), L33F_V (5.8), H69N (1.8)||K43 (4.1)||8|
|7118||L10F (99.5), V11I (71.2), L33F (99.3), M46L (99.4), G51A (100), I54M (99.2), A71V (99.8), G73A (99.7), I84V (96.5), L90M (97.4)||L19I (2.5), C67Y (1.1)||L90I (1.6)||8|
|7859||L10I (99.6), V32I (99.9), L33F (99.9), M46I (99.7), I47V (99.7), I54M (99.1), A71V (100), T74P (99.7), I84V (99.7), L89V (99.7), L90M (99.6)||E34G (1.2)||E65K (1.6), C67Y (1.2)||R87S (1.3)||12|
|14311||L10F (86.8), V11I (99.5), V32I (99.8), M46I (99.7), I47V (99.9), I54M (99.5), G73T (99.9), I84V (99.6), L89V (100), L90M (99.4)||L10Y (12.8)||L63T (3.1)||14|
|38129||L10I (99.7), V11I (84.3), V32I (99.9), L33F (59.2), M46I (99.9), I47V (99.8), I54M (99.0), Q58E (99.6), A71V (59.1), A71I (34.6), G73S (99.8), I84V (71.1), L89V (79.1), L90M (99.5)||I50V (20.2), I66V (17.7), V11L (15.5), E35N (10.7), A71T (6.3), I66F (2.6)||Q92K (3.1), V82I (3.0)||L89 (20.7), R57 (1.6)||G51R (1.7)||6|
aMutations in bold are major PI resistance mutations. Underlined italicized mutations were present as part of electrophoretic mixtures.
bVariants with the consensus B amino acid in a sample for which the direct PCR sequence had a difference from consensus B.
cVariants present in <0.01% of non-hypermutated sequences in the Stanford HIV Drug Resistance Database.
dMinority variants that did not result in an amino acid difference from the direct PCR Sanger sequence.
Keywords: drug resistance, deep sequencing, minority variants, Sanger sequencing.
Previous Document: Ring-opening polymerization reaction of polyhedral oligomeric silsesquioxanes (POSSs) for preparatio...
Next Document: Treatment of Candida famata bloodstream infections: case series and review of the literature.